PMID- 31198488
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231012
IS  - 1939-4551 (Print)
IS  - 1939-4551 (Electronic)
IS  - 1939-4551 (Linking)
VI  - 12
IP  - 5
DP  - 2019
TI  - Developing pharmacogenetic screening methods for an emergent country: Vietnam.
PG  - 100037
LID - 10.1016/j.waojou.2019.100037 [doi]
LID - 100037
AB  - BACKGROUND: The finding of strong associations between certain human leukocyte 
      antigen (HLA) genotypes and the development of severe cutaneous adverse drug 
      reactions (SCARs), [for example, HLA-B*57:01 and abacavir (ABC), HLA-B*15:02 and 
      carbamazepine (CBZ) and HLA-B*58:01 and allopurinol], has led to HLA screening 
      being used to prevent SCARs. Screening has been shown to be of great benefit in a 
      number of studies. Clinical translation from bench to bedside, however, depends 
      upon the development of simple, rapid and cost-effective assays to detect these 
      risk alleles. In highly populated developing countries such as Vietnam, where 
      there is a high prevalence of HLA-B*15:02 and HLA-B*58:01 correlating with a high 
      incidence of CBZ- and allopurinol-induced SCARs, the crucial factor in the 
      implementation of comprehensive screening programs to detect these major risk HLA 
      alleles is the availability of suitable assays. BODY: We have summarized the role 
      and economic benefits of HLA screening, reviewed published HLA screening methods 
      used currently in pharmacogenetic screening and examined the advantages and 
      disadvantages of assays developed specifically for use in screening for risk 
      alleles in the prevention of HLA-associated SCARs in Vietnam. CONCLUSION: The 
      optimal approach we propose may serve as a template for the development of 
      screening programs in other emergent countries.
FAU - Nguyen, Dinh Van
AU  - Nguyen DV
AD  - Respiratory, Allergy and Clinical Immunology, Vinmec International Hospital, 
      Times City and Vin University, Hanoi, Viet Nam.
AD  - Northern Clinical School, The University of Sydney, Sydney, Australia.
AD  - Department of Allergy and Clinical Immunology, Hanoi Medical University, Hanoi, 
      Viet Nam.
FAU - Vidal, Christopher
AU  - Vidal C
AD  - Northern Clinical School, The University of Sydney, Sydney, Australia.
FAU - Chu, Hieu Chi
AU  - Chu HC
AD  - Center of Allergology and Clinical Immunology, Bach Mai Hospital, Hanoi, Viet 
      Nam.
FAU - van Nunen, Sheryl
AU  - van Nunen S
AD  - Northern Clinical School, The University of Sydney, Sydney, Australia.
AD  - Department of Clinical Immunology and Allergy, Royal North Shore Hospital, 
      Sydney, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190606
PL  - United States
TA  - World Allergy Organ J
JT  - The World Allergy Organization journal
JID - 101481283
PMC - PMC6558218
OTO - NOTNLM
OT  - HLA
OT  - HLA screening
OT  - HLA typing
OT  - Real-time PCR
OT  - SCARs
OT  - Severe cutaneous adverse drug reactions
EDAT- 2019/06/15 06:00
MHDA- 2019/06/15 06:01
PMCR- 2019/06/06
CRDT- 2019/06/15 06:00
PHST- 2018/12/12 00:00 [received]
PHST- 2019/03/24 00:00 [revised]
PHST- 2019/05/01 00:00 [accepted]
PHST- 2019/06/15 06:00 [entrez]
PHST- 2019/06/15 06:00 [pubmed]
PHST- 2019/06/15 06:01 [medline]
PHST- 2019/06/06 00:00 [pmc-release]
AID - S1939-4551(19)30666-0 [pii]
AID - 100037 [pii]
AID - 10.1016/j.waojou.2019.100037 [doi]
PST - epublish
SO  - World Allergy Organ J. 2019 Jun 6;12(5):100037. doi: 
      10.1016/j.waojou.2019.100037. eCollection 2019.